| Year |
Citation |
Score |
| 2020 |
Lee SY, Kim EK, Kim JY, Park TK, Choi SH, Im YH, Kim MY, Park YH, Kim DK. The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. Scientific Reports. 10: 18647. PMID 33122662 DOI: 10.1038/s41598-020-75620-6 |
0.306 |
|
| 2020 |
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet. Oncology. PMID 32171426 DOI: 10.1016/S1470-2045(19)30863-0 |
0.304 |
|
| 2019 |
Sim SH, Park IH, Jung KH, Kim SB, Ahn JH, Lee KH, Im SA, Im YH, Park YH, Sohn J, Kim YJ, Lee S, Kim HJ, Chae YS, Park KH, et al. Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). British Journal of Cancer. PMID 31690831 DOI: 10.1038/s41416-019-0618-z |
0.316 |
|
| 2018 |
Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, Lee SC, Ahn JS, Park SW, Im YH, Jeon ES, Park YH. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 30177584 DOI: 10.4143/crt.2018.262 |
0.304 |
|
| 2017 |
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, et al. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. European Journal of Cancer (Oxford, England : 1990). 86: 385-393. PMID 29100193 DOI: 10.1016/j.ejca.2017.10.002 |
0.316 |
|
| 2016 |
Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY. Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. Journal of Pathology and Translational Medicine. PMID 28013533 DOI: 10.4132/jptm.2016.10.05 |
0.312 |
|
| 2016 |
Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 27709313 DOI: 10.1007/s00520-016-3429-2 |
0.445 |
|
| 2016 |
Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, et al. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 27488876 DOI: 10.4143/crt.2016.191 |
0.452 |
|
| 2016 |
Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. The Lancet. Oncology. PMID 26822398 DOI: 10.1016/S1470-2045(15)00540-9 |
0.322 |
|
| 2015 |
Park K, Choi MK, Jung HH, Do IG, Lee KH, Ahn T, Kil WH, Kim SW, Lee JE, Nam SJ, Kim DH, Ahn JS, Im YH, Park YH. Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget. PMID 26009992 DOI: 10.18632/oncotarget.4119 |
0.309 |
|
| 2015 |
Hong JY, Park YH, Choi MK, Jung HA, Lee SJ, Ahn JS, Im YH. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clinical Breast Cancer. PMID 25997855 DOI: 10.1016/j.clbc.2015.04.004 |
0.325 |
|
| Show low-probability matches. |